BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

BioNexus Gene Lab Corp. (NASDAQ:BGLC) saw a large decline in short interest in January. As of January 15th, there was short interest totaling 17,038 shares, a decline of 38.3% from the December 31st total of 27,606 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average trading volume of 6,680 shares, the days-to-cover ratio is presently 2.6 days. Based on an average trading volume of 6,680 shares, the days-to-cover ratio is presently 2.6 days. Approximately 0.7% of the company’s shares are short sold.

BioNexus Gene Lab Trading Down 3.7%

Shares of NASDAQ:BGLC traded down $0.10 during trading on Friday, reaching $2.55. 12,116 shares of the company traded hands, compared to its average volume of 27,334. BioNexus Gene Lab has a 52-week low of $2.01 and a 52-week high of $15.60. The firm has a market capitalization of $6.02 million, a price-to-earnings ratio of -3.36 and a beta of 5.26. The business’s fifty day moving average is $3.90 and its 200-day moving average is $4.82.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNexus Gene Lab in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioNexus Gene Lab has a consensus rating of “Sell”.

BioNexus Gene Lab Company Profile

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.